The Form 4 filing, an SEC report of an insider’s stock transactions, was submitted on November 12, 2026. That was three days after the sale. It lists Jeffrey Ryan Stewart as AbbVie’s executive vice president and chief commercial officer.
AbbVie is in the healthcare sector and the general drug manufacturers industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-09 |
| Date of Latest Transaction | 2026-11-09 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 40,619 |
| Price | $293.60 |
| Total Transaction Value | $11,925,738.40 |
| Insider | |
| Ticker Symbol | ABBV |
| Company | AbbVie Inc. |
| Insider Name | Stewart Jeffrey Ryan |
| Insider Title | EVP, CHIEF COMMERCIAL OFFICER |
| Sector - Industry | Healthcare - Drug Manufacturers - General |
| Holdings | |
| Total Shares Owned After Transaction | 83,171 |
| Position Size Change | 32.81% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S. Jeffrey Ryan Stewart sold ABBV shares in one transaction.
What was the average price of the transaction?
The reported average price was $293.60 per share. This price applies to the single sale reported for November 9, 2026.
How did this transaction affect the insider's holdings?
Jeffrey Ryan Stewart sold 40,619 shares and reported 83,171 shares owned afterward. Those figures put the reported balance before the sale at 123,790 shares. He sold 32.81% of that starting balance.
What's the total transaction value?
The total transaction value was $11,925,738.40. That amount covers all 40,619 shares in the one reported sale.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Filing footnotes were not included in the available details, so further terms remain unknown. The reason for the sale is also unknown.
For research purposes only; not investment advice.